|
|
|
|
|
|
Sponsors and Collaborators: |
German Institute of Human Nutrition Danone Research Foundation Leiber Company |
Information provided by: | German Institute of Human Nutrition |
ClinicalTrials.gov Identifier: | NCT00403689 |
Insoluble (1,3),(1,6)-beta-D-glucan from bakers yeast are indigestible polysaccharides. Previous studies indicate that the intake of insoluble dietary fiber is strongly associated with reduced risk of type 2 diabetes and cardiovascular disease. However, the mechanisms leading to this phenomenon are largely unknown.
There are close relations between metabolic and inflammatory pathways, and a number of hormones, cytokines, signal proteins, bioactive lipids, and transcription factors have been shown to be involved in both systems.
Beta-D-glucans have been suggested to play a role as so called biological response modifiers. Studies in animals indicate that even small doses of (1,3),(1,6)-beta-D-glucan may have beneficial effects on immune activity, i.e. by reducing the secretion of inflammatory factors.
We hypothesise that the intake of isolated (1,3), (1,6)-beta-D-glucan from bakers yeast improves inflammatory makers and insulin-sensitivity in overweight subjects with increased C-reactive protein concentrations at baseline.
Condition | Intervention |
Overweight |
Dietary Supplement: Beta-D-Glucan Dietary Supplement: placebo |
MedlinePlus related topics: | Dietary Supplements |
ChemIDplus related topics: | Insulin Starch |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Crossover Assignment, Efficacy Study |
Official Title: | Effects of (1,3), (1,6)-Beta-D-Glucan on Insulin Sensitivity and Inflammatory Markers of the Metabolic Syndrome |
Enrollment: | 11 |
Study Start Date: | November 2006 |
Study Completion Date: | March 2008 |
Primary Completion Date: | March 2008 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
x: Experimental
capsules containing beta glycan
|
Dietary Supplement: Beta-D-Glucan
1,5 g Beta-D-Glucan daily
|
y: Placebo Comparator
capsules containing placebo (waxy maize starch)
|
Dietary Supplement: placebo
1.5 g waxy maize starch daily
|
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
Germany | |||||
German Institute of Human Nutrition, Department of Clinical Nutrition, Potsdam-Rehbrücke | |||||
Nuthetal, Germany, 14558 |
German Institute of Human Nutrition |
Danone Research Foundation |
Leiber Company |
Principal Investigator: | Martin O Weickert, MD | German Institute of Human Nutrition |
Study Chair: | Andreas FH Pfeiffer, Prof | German Institute of Human Nutrition |
Related Info 
  |
Related Info 
  |
Responsible Party: | German Institute of Human Nutrition, Department of Human Nutrition ( Dr. Martin O. Weickert ) |
Study ID Numbers: | MOW_bGlucan |
First Received: | November 24, 2006 |
Last Updated: | March 7, 2008 |
ClinicalTrials.gov Identifier: | NCT00403689 |
Health Authority: | Germany: Ethics Commission |
|
|